Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track DRMA with free AI briefings, catalyst countdowns, and dilution alerts.

DRMA · Dermata Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4.4M Cash on Hand

5.4mo Cash Runway

Follow DRMA by email Get an email when DRMA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about DRMA, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Mar 2025 · Phase 3 · Results Expected · DMT310-009 Topical in the Treatment of Acne Vulgaris
Registry primary completion date, not a results date
May 2020 · Phase 2 · Results Expected · DMT310-003 Topical in the Treatment of Acne Vulgaris
Registry primary completion date, not a results date
Dec 2018 · Phase 2 · Results Expected · DMT310-001 Topical in the Treatment of Acne Vulgaris
Registry primary completion date, not a results date
Aug 2017 · Phase 2 · Results Expected · DMT210 Topical Gel in the Treatment of Acne Rosacea
Registry primary completion date, not a results date
Jul 2017 · Phase 2 · Results Expected · DMT210 Topical Gel in the Treatment of Atopic Dermatitis
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
DMT310	Acne Vulgaris	Phase 3 · NCT06090721	Completed
DMT210 Topical Gel	Atopic Dermatitis	Phase 2 · NCT02949960	Completed
DMT210 Topical Gel 5%	Acne Rosacea	Phase 2 · NCT03003104	Completed
Topical Powder	Acne Rosacea	Phase 2 · NCT05108025	Unknown

Also used in these trials (approved or third-party drugs, not DRMA's own candidates): Hydrogen Peroxide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

DRMA holds $4.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.5M/quarter from operations, an estimated runway of 5.4 months at that rate (BioRadar estimate, not company guidance).

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DRMA files for a raise →

Get the full DRMA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DRMA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z